These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30711576)

  • 1. Luxturna: FDA documents reveal the value of a costly gene therapy.
    Darrow JJ
    Drug Discov Today; 2019 Apr; 24(4):949-954. PubMed ID: 30711576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):53-55. PubMed ID: 29635265
    [No Abstract]   [Full Text] [Related]  

  • 3. Bilateral Subretinal Voretigene Neparvovec-rzyl (Luxturna) Gene Therapy.
    Weng CY
    Ophthalmol Retina; 2019 May; 3(5):450. PubMed ID: 31044739
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.
    Maguire AM; Bennett J; Aleman EM; Leroy BP; Aleman TS
    Mol Ther; 2021 Feb; 29(2):442-463. PubMed ID: 33278565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl.
    Bennett J; Maguire AM
    Cold Spring Harb Perspect Med; 2023 May; 13(5):. PubMed ID: 36167727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.
    Kang C; Scott LJ
    Mol Diagn Ther; 2020 Aug; 24(4):487-495. PubMed ID: 32535767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voretigene neparvovec-rzyl for treatment of
    Ciulla TA; Hussain RM; Berrocal AM; Nagiel A
    Expert Opin Biol Ther; 2020 Jun; 20(6):565-578. PubMed ID: 32149547
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease.
    Zimmermann M; Lubinga SJ; Banken R; Rind D; Cramer G; Synnott PG; Chapman RH; Khan S; Carlson J
    Value Health; 2019 Feb; 22(2):161-167. PubMed ID: 30711060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
    Russell S; Bennett J; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; McCague S; Cross D; Marshall KA; Walshire J; Kehoe TL; Reichert H; Davis M; Raffini L; George LA; Hudson FP; Dingfield L; Zhu X; Haller JA; Sohn EH; Mahajan VB; Pfeifer W; Weckmann M; Johnson C; Gewaily D; Drack A; Stone E; Wachtel K; Simonelli F; Leroy BP; Wright JF; High KA; Maguire AM
    Lancet; 2017 Aug; 390(10097):849-860. PubMed ID: 28712537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
    Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J
    Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visual Acuity, Retinal Morphology, and Patients' Perceptions after Voretigene Neparovec-rzyl Therapy for RPE65-Associated Retinal Disease.
    Sengillo JD; Gregori NZ; Sisk RA; Weng CY; Berrocal AM; Davis JL; Mendoza-Santiesteban CE; Zheng DD; Feuer WJ; Lam BL
    Ophthalmol Retina; 2022 Apr; 6(4):273-283. PubMed ID: 34896323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy.
    Lopez J; Borchert M; Lee TC; Nagiel A
    Br J Ophthalmol; 2023 Mar; 107(3):299-301. PubMed ID: 35835501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease.
    Johnson S; Buessing M; O'Connell T; Pitluck S; Ciulla TA
    JAMA Ophthalmol; 2019 Oct; 137(10):1115-1123. PubMed ID: 31318398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.
    Maguire AM; Russell S; Chung DC; Yu ZF; Tillman A; Drack AV; Simonelli F; Leroy BP; Reape KZ; High KA; Bennett J
    Ophthalmology; 2021 Oct; 128(10):1460-1468. PubMed ID: 33798654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subretinal Injection of Voretigene Neparvovec-rzyl in a Patient With RPE65-Associated Leber's Congenital Amaurosis.
    Hussain RM; Tran KD; Maguire AM; Berrocal AM
    Ophthalmic Surg Lasers Imaging Retina; 2019 Oct; 50(10):661-663. PubMed ID: 31671202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The first gene therapy for
    Ferraz Sallum JM; Godoy J; Kondo A; Kutner JM; Vasconcelos H; Maia A
    Ophthalmic Genet; 2022 Aug; 43(4):550-554. PubMed ID: 35416119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Autofluorescence Following Gene Therapy With Voretigene Neparvovec.
    Levi SR; Oh JK; de Carvalho JRL; Mahajan VB; Tsang SH; Sparrow JR
    JAMA Ophthalmol; 2020 Aug; 138(8):919-921. PubMed ID: 32556084
    [No Abstract]   [Full Text] [Related]  

  • 18. Frequency of
    Kahraman NS; Öner A; Özkul Y; Dündar M
    Turk J Ophthalmol; 2022 Aug; 52(4):270-275. PubMed ID: 36017377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Gene Therapy Treatments for Inherited Retinal Diseases.
    Bakall B; Hariprasad SM; Klein KA
    Ophthalmic Surg Lasers Imaging Retina; 2018 Jul; 49(7):472-478. PubMed ID: 30021033
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.